For example, in mutant RUNX1-expressed AML cells, deleting the RUNX1 enhancer within its intragenic SE using CRISPR/Cas9 leads to the suppressed expression of RUNX1, subsequently decelerating cell growth and increasing cell death [207]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.